Perspective Therapeutics cohort safety and efficacy data set for NANETS 2026 presentation
CATX•Perspective Therapeutics secured acceptance to present interim safety and efficacy results from its [²¹²Pb]VMT-α-NET trial on Nov. 5 at the NANETS 2026 symposium in Las Vegas. Additional readouts from later cohorts remain pending.
1. Presentation accepted
The interim results are from a trial of [²¹²Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors. Earlier interim data were presented at ASCO in May 2026.
2. Further readouts pending
Management is positioning the program as an alpha-emitting radiopharmaceutical option for patients with unresectable or metastatic disease who have not received prior RPT. The company plans further disclosures across 2026 and 2027.
